Oramed Pharmaceuticals Inc.
ORMP · NASDAQ
Market closed$4.03$-0.020000 (-0.49%)After hours $4.00 · -0.74%
Key statistics
Previous close$4.05
Open$3.98
Day high$4.13
Day low$3.98
52-week high$5.19
52-week low$1.98
Market cap164.93M
Volume183.62K
Average volume299.78K
P/E ratio2.09
Forward P/E—
EPS1.93
Dividend yield+6.20%
Market context
Why it moved
ORMP edged slightly lower amid a continued bearish technical trend, with the stock trading below its key short- and medium-term moving averages, reflecting subdued investor sentiment and limited buying interest.
What is happening
Recent company-specific developments and publisher coverage.
ad-hoc-news.de · July 17, 2026Oramed stock trades quietly as diabetes pill strategy pivots after FDA setbackAd Hoc News · July 8, 2026Oramed Pharmaceuticals highlights oral drug platform as investors assess long-term prospectsPR Newswire · June 25, 2026Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance SheetPR Newswire · June 17, 2026Oramed Pharmaceuticals to Join Russell 2000® and Russell 3000® IndexesInvesting.com · June 17, 2026Oramed Pharmaceuticals to join Russell 2000, 3000 indexesSeeking Alpha · May 22, 2026Oramed Pharmaceuticals: 'Hold' On Oral Insulin Drug Failure Pivot And New Strategic Investment DirectionPR Newswire · January 13, 2026Oramed and Lifeward Announce Strategic TransactionZacks Investment Research · October 12, 2020ORMP: ORMD-0801 in Phase 3 TD2 and NASH Clinical Studies Mt Newswire · July 7, 2026Lifeward Enters Securities Purchase Agreement Under Oramed Financing Framework Mt Newswire · March 25, 2026Lifeward Closes Oramed Partnership, Acquires Oratech Pharma Benzinga · March 25, 2026Lifeward Closes The Strategic Partnership Agreement With Oramed Pharmaceuticals Mt Newswire · March 13, 2026Lifeward Shareholders Approve Share Issuance for Oramed Partnership Benzinga · March 13, 2026Lifeward Shareholders Approve Issuance Of Ordinary Shares Over Previously Announced Collaboration Deal With Oramed Pharmaceuticals Mt Newswire · January 13, 2026Lifeward Obtains Investment, Protein Oral Delivery Technology From Oramed Benzinga · January 13, 2026Lifeward To Issue $10M In Senior Secured Convertible Notes In A Private Placement, Of Which Oramed To Invest $9M, And An Additional Milestone-Based $10M Senior Secured Convertible Note, Of Which Oramed Will Invest $9M, Each With 100% Warrant Coverage Benzinga · January 13, 2026Lifeward To Acquire Oramed's POD Technology And Secure Up To $47M Strategic Investment As Oramed Takes Up To 49.99% Stake